Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy

Anupama Mohanram, Zhongxin Zhang, Shahnaz Shahinfar, William F. Keane, Barry M. Brenner, Robert D. Toto

Research output: Contribution to journalArticle

146 Citations (Scopus)

Abstract

Background. Diabetic nephropathy is the leading cause of end-stage renal disease (ESRD). Anemia is common in diabetics with nephropathy; however, the impact of anemia on progression to ESRD has not been carefully examined. Methods. We studied the relationship between baseline hemoglobin concentration (Hb) and progression of diabetic nephropathy to ESRD in 1513 participants enrolled in Reduction in Endpoints in NIDDM with the Angiotensin II Antagonist Losartan study and followed for an average of 3.4 years. Multivariate Cox proportional hazards models were used to analyze the relationship between Hb and ESRD, after adjusting for predictors for ESRD. Analyses were performed with Hb stratified by quartile: first quartile <11.3 g/dL, second quartile 11.3 to 12.5 g/dL, third quartile 12.6 to 13.8 g/dL, and fourth quartile ≥13.8 g/dL (reference) and as a continuous variable. Results. Baseline hemoglobin concentration was correlated with subsequent development of ESRD. After adjustment for predictors of ESRD, the hazard ratios for the first, second, and third Hb quartiles were 1.99 (95% CI, 1.34-2.95), 1.61 (95% CI 1.08-2.41), and 1.87 (95% CI 1.25-2.80). With hemoglobin as a continuous variable, the adjusted hazard ratio was 0.90 (95% CI 0.84-0.96, P = 0.0013). The average increase in adjusted relative risk was 11% for each 1 g/dL decrease in hemoglobin concentration. Conclusion. Our data suggest that even mild anemia, Hb <13.8 g/dL increases risk for progression to ESRD. Hemoglobin is an independent risk factor for progression of nephropathy to ESRD in type 2 diabetes.

Original languageEnglish (US)
Pages (from-to)1131-1138
Number of pages8
JournalKidney International
Volume66
Issue number3
DOIs
StatePublished - Sep 2004

Fingerprint

Type 2 Diabetes Mellitus
Chronic Kidney Failure
Anemia
Hemoglobins
Diabetic Nephropathies
Losartan
Proportional Hazards Models
Angiotensin II

Keywords

  • Anemia
  • Diabetic nephropathy
  • ESRD
  • Multivariate analysis
  • Progression

ASJC Scopus subject areas

  • Nephrology

Cite this

Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy. / Mohanram, Anupama; Zhang, Zhongxin; Shahinfar, Shahnaz; Keane, William F.; Brenner, Barry M.; Toto, Robert D.

In: Kidney International, Vol. 66, No. 3, 09.2004, p. 1131-1138.

Research output: Contribution to journalArticle

Mohanram, Anupama ; Zhang, Zhongxin ; Shahinfar, Shahnaz ; Keane, William F. ; Brenner, Barry M. ; Toto, Robert D. / Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy. In: Kidney International. 2004 ; Vol. 66, No. 3. pp. 1131-1138.
@article{ac0c8cbefde840bebab879656d2dbd4a,
title = "Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy",
abstract = "Background. Diabetic nephropathy is the leading cause of end-stage renal disease (ESRD). Anemia is common in diabetics with nephropathy; however, the impact of anemia on progression to ESRD has not been carefully examined. Methods. We studied the relationship between baseline hemoglobin concentration (Hb) and progression of diabetic nephropathy to ESRD in 1513 participants enrolled in Reduction in Endpoints in NIDDM with the Angiotensin II Antagonist Losartan study and followed for an average of 3.4 years. Multivariate Cox proportional hazards models were used to analyze the relationship between Hb and ESRD, after adjusting for predictors for ESRD. Analyses were performed with Hb stratified by quartile: first quartile <11.3 g/dL, second quartile 11.3 to 12.5 g/dL, third quartile 12.6 to 13.8 g/dL, and fourth quartile ≥13.8 g/dL (reference) and as a continuous variable. Results. Baseline hemoglobin concentration was correlated with subsequent development of ESRD. After adjustment for predictors of ESRD, the hazard ratios for the first, second, and third Hb quartiles were 1.99 (95{\%} CI, 1.34-2.95), 1.61 (95{\%} CI 1.08-2.41), and 1.87 (95{\%} CI 1.25-2.80). With hemoglobin as a continuous variable, the adjusted hazard ratio was 0.90 (95{\%} CI 0.84-0.96, P = 0.0013). The average increase in adjusted relative risk was 11{\%} for each 1 g/dL decrease in hemoglobin concentration. Conclusion. Our data suggest that even mild anemia, Hb <13.8 g/dL increases risk for progression to ESRD. Hemoglobin is an independent risk factor for progression of nephropathy to ESRD in type 2 diabetes.",
keywords = "Anemia, Diabetic nephropathy, ESRD, Multivariate analysis, Progression",
author = "Anupama Mohanram and Zhongxin Zhang and Shahnaz Shahinfar and Keane, {William F.} and Brenner, {Barry M.} and Toto, {Robert D.}",
year = "2004",
month = "9",
doi = "10.1111/j.1523-1755.2004.00863.x",
language = "English (US)",
volume = "66",
pages = "1131--1138",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy

AU - Mohanram, Anupama

AU - Zhang, Zhongxin

AU - Shahinfar, Shahnaz

AU - Keane, William F.

AU - Brenner, Barry M.

AU - Toto, Robert D.

PY - 2004/9

Y1 - 2004/9

N2 - Background. Diabetic nephropathy is the leading cause of end-stage renal disease (ESRD). Anemia is common in diabetics with nephropathy; however, the impact of anemia on progression to ESRD has not been carefully examined. Methods. We studied the relationship between baseline hemoglobin concentration (Hb) and progression of diabetic nephropathy to ESRD in 1513 participants enrolled in Reduction in Endpoints in NIDDM with the Angiotensin II Antagonist Losartan study and followed for an average of 3.4 years. Multivariate Cox proportional hazards models were used to analyze the relationship between Hb and ESRD, after adjusting for predictors for ESRD. Analyses were performed with Hb stratified by quartile: first quartile <11.3 g/dL, second quartile 11.3 to 12.5 g/dL, third quartile 12.6 to 13.8 g/dL, and fourth quartile ≥13.8 g/dL (reference) and as a continuous variable. Results. Baseline hemoglobin concentration was correlated with subsequent development of ESRD. After adjustment for predictors of ESRD, the hazard ratios for the first, second, and third Hb quartiles were 1.99 (95% CI, 1.34-2.95), 1.61 (95% CI 1.08-2.41), and 1.87 (95% CI 1.25-2.80). With hemoglobin as a continuous variable, the adjusted hazard ratio was 0.90 (95% CI 0.84-0.96, P = 0.0013). The average increase in adjusted relative risk was 11% for each 1 g/dL decrease in hemoglobin concentration. Conclusion. Our data suggest that even mild anemia, Hb <13.8 g/dL increases risk for progression to ESRD. Hemoglobin is an independent risk factor for progression of nephropathy to ESRD in type 2 diabetes.

AB - Background. Diabetic nephropathy is the leading cause of end-stage renal disease (ESRD). Anemia is common in diabetics with nephropathy; however, the impact of anemia on progression to ESRD has not been carefully examined. Methods. We studied the relationship between baseline hemoglobin concentration (Hb) and progression of diabetic nephropathy to ESRD in 1513 participants enrolled in Reduction in Endpoints in NIDDM with the Angiotensin II Antagonist Losartan study and followed for an average of 3.4 years. Multivariate Cox proportional hazards models were used to analyze the relationship between Hb and ESRD, after adjusting for predictors for ESRD. Analyses were performed with Hb stratified by quartile: first quartile <11.3 g/dL, second quartile 11.3 to 12.5 g/dL, third quartile 12.6 to 13.8 g/dL, and fourth quartile ≥13.8 g/dL (reference) and as a continuous variable. Results. Baseline hemoglobin concentration was correlated with subsequent development of ESRD. After adjustment for predictors of ESRD, the hazard ratios for the first, second, and third Hb quartiles were 1.99 (95% CI, 1.34-2.95), 1.61 (95% CI 1.08-2.41), and 1.87 (95% CI 1.25-2.80). With hemoglobin as a continuous variable, the adjusted hazard ratio was 0.90 (95% CI 0.84-0.96, P = 0.0013). The average increase in adjusted relative risk was 11% for each 1 g/dL decrease in hemoglobin concentration. Conclusion. Our data suggest that even mild anemia, Hb <13.8 g/dL increases risk for progression to ESRD. Hemoglobin is an independent risk factor for progression of nephropathy to ESRD in type 2 diabetes.

KW - Anemia

KW - Diabetic nephropathy

KW - ESRD

KW - Multivariate analysis

KW - Progression

UR - http://www.scopus.com/inward/record.url?scp=4344713002&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4344713002&partnerID=8YFLogxK

U2 - 10.1111/j.1523-1755.2004.00863.x

DO - 10.1111/j.1523-1755.2004.00863.x

M3 - Article

C2 - 15327408

AN - SCOPUS:4344713002

VL - 66

SP - 1131

EP - 1138

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 3

ER -